Reports of Biochemistry
and Molecular Biology
Sat, Aug 13, 2022
[Archive]
Volume 11, Issue 1 (Vol.11 No.1 Apr 2022)
rbmb.net 2022, 11(1): 83-88 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Abdulaali Abed T, Abdulla A A. Correlation of -475 IL-2 Promoter Gene Polymorphisms and the Levels of Serum IL-2 on the Risk of Multiple Sclerosis. rbmb.net. 2022; 11 (1) :83-88
URL: http://rbmb.net/article-1-717-en.html
URL: http://rbmb.net/article-1-717-en.html
Department of Biology, College of Sciences, University of Babylon, Iraq.
Abstract: (723 Views)
Background: The aim of present study is to asset the IL-2 promoter gene (SNP -475) as a candidate gene for multiple sclerosis (MS) susceptibility.
Methods: This study included 70 patients with relapsing – remitting multiple sclerosis (RRMS) and 50 healthy controls. Following the extraction of genomic DNA from peripheral blood, frequency of genotypes and alleles of SNP -475 was calculated using Restriction fragment length polymorphism-polymer chain
reaction (RFLP-PCR) and then the results were analyzed statistically.
Results: The results revealed the unusual ratio for the heterozygous (AT) was 1.6972 indicating that heterozygous patients were at higher risk of multiple sclerosis than wild homozygous (AA), and homomutant (TT). The results show protective role for - 475 IL-2 promoter among individuals with multiple
sclerosis, (O.R: 0.4872; C.I. 95%: 0.1617- 1.4680) and (O.R: 0.9275; C.I. 95%: 0.2476 - 3.4745) for both AA and TT genotypes, respectively.
Conclusions: Our results showed that in this population of Iraqi patients, the AT genotype / A allele of -475 IL-2 promoter gene SNP may include attributed factors for MS predisposition.
Methods: This study included 70 patients with relapsing – remitting multiple sclerosis (RRMS) and 50 healthy controls. Following the extraction of genomic DNA from peripheral blood, frequency of genotypes and alleles of SNP -475 was calculated using Restriction fragment length polymorphism-polymer chain
reaction (RFLP-PCR) and then the results were analyzed statistically.
Results: The results revealed the unusual ratio for the heterozygous (AT) was 1.6972 indicating that heterozygous patients were at higher risk of multiple sclerosis than wild homozygous (AA), and homomutant (TT). The results show protective role for - 475 IL-2 promoter among individuals with multiple
sclerosis, (O.R: 0.4872; C.I. 95%: 0.1617- 1.4680) and (O.R: 0.9275; C.I. 95%: 0.2476 - 3.4745) for both AA and TT genotypes, respectively.
Conclusions: Our results showed that in this population of Iraqi patients, the AT genotype / A allele of -475 IL-2 promoter gene SNP may include attributed factors for MS predisposition.
Type of Article: Original Article |
Subject:
Molecular Biology
Received: 2021/05/22 | Accepted: 2021/10/24 | Published: 2022/05/26
Received: 2021/05/22 | Accepted: 2021/10/24 | Published: 2022/05/26
References
1. Principles of Neurology, 6th Edition: Companion Handbook. Adams RD, Victor M, Maurice R, Ropper AH. Published by Mcgraw-Hill (Tx), 1998.
2. Charles J, Valenti L, Britt H. Multiple sclerosis. Aust Fam Physician. 2011;40(12):947-55.
3. Goverman J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol. 2009;9(6): 393-407. [DOI:10.1038/nri2550] [PMID] [PMCID]
4. Kampman MT, Eriksen EF, Holmoy T. Multiple sclerosis, a cause of secondary osteoporosis? What is the evidence and what are the clinical implications?. Acta Neurol Scand Suppl. 2011;(191):44-9. [DOI:10.1111/j.1600-0404.2011.01543.x] [PMID]
5. Yousefipour G, Erfani N, Momtahan M, Moghaddasi H, Ghaderi A. CTLA4 exon 1 and promoter polymorphisms in patients with multiple sclerosis. Acta Neurol Scand. 2009;120(6):424-429. [DOI:10.1111/j.1600-0404.2009.01177.x] [PMID]
6. Browne P, Chandraratna, DA, Good C, Tremlett H, Baker Ch, et al. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology. 2014;83(11):1022-1024. [DOI:10.1212/WNL.0000000000000768] [PMID] [PMCID]
7. Cantrell DA, Smith KA. The mterleukm-2 T-cell system: a new cell growth model. Science. 1984;224(4655):1312-16. [DOI:10.1126/science.6427923] [PMID]
8. John S, Turner D, Donn R, Sinnott P, Worthington J, Ollier WE et al. Two novel biallelic polymorphisms in the IL-2 gene. Eur J Immunogenet. 1998;25(6):419-20. [DOI:10.1046/j.1365-2370.1998.00139.x] [PMID]
9. Fedetz M, Alcina A, Fernández O, Guerrero M, Delgado C, Matesanz F. Analysis of -631 and -475 interleukin-2 promoter single nucleotide polymorphisms in multiple sclerosis. Eur J Immunogenet. 2002;29(5):389-90. [DOI:10.1046/j.1365-2370.2002.00338.x] [PMID]
10. Milo R, Miller A. Revised diagnostic criteria of multiple sclerosis. Autoimmune Rev.2014;13(4-5):518-24. [DOI:10.1016/j.autrev.2014.01.012] [PMID]
11. Sambrook, J. and Russell, D.W. (2001) Molecular Cloning A Laboratory Manual. 3rd Edition, Vol. 1, Cold Spring Harbor Laboratory Press, New York. Laboratory Press, Cold Spring Harbor, New York. 2001.
12. Farrar JJ, Benjamin WR, Hdfiker, ML, Howard M, Farra WJ, Fuller-Farrar J. The biochemistry, biology, and role of interleukin 2 in the induction of cytotoxic T cell and antibody-forming B cell responses. Immunol Rev. 1982;63:129-66. [DOI:10.1111/j.1600-065X.1982.tb00414.x] [PMID]
13. Gallo P, Plccmo, M Pagm, S and Tavolato B. Interleukln-2 levels in serum and cerebrospmal fluid of multtple sclerosis patients. Ann Neurol. 1988;24(6):795-7. [DOI:10.1002/ana.410240618] [PMID]
14. Gallo P, Piccinno MG, Pagni S, Argentiero V, Giometto B, Bozza F, Tavolato B. Immune activation in multiple sclerosis: study of IL-2, sIL-2R, and gamma-IFN levels in serum and cerebrospinal fluid. J Neurol Sci. 1989;92(1):9-15. Trotter J L, Van der Veen R, D B Clifford. Serial studies of serum mterleukm-2 m chromc progress, multiple sclerosis patient: occurrence of bursts and effect of cyclosporine. J Neuroimmunol. 1990;28(1):9-14. [DOI:10.1016/0165-5728(90)90036-M]
15. Gallo P, Plcmno MG, Tavolato B, slain A. A longitudinal study on IL-2, SIL-2R, IL-4 and IFN-gamma in multiple sclerosis CSF and serum. Journal of the Neurological Sciences. 1991;101(2)227-232. [DOI:10.1016/0022-510X(91)90050-H]
16. Bellamy AS, Calder VL, Feldmann M, Davlson, AN. The distribution of mterleukin-2 receptor bearing lymphocytes multiple sclerosis evidence for a key role of activated lymphocytes. Clin Exp Immunol. 1985;61(2):248-256.
17. Selmaj K, Plater-Zyberk C, Rockett K A, Maml R N, Alam R Perkm, G D Perkin, et al. Multiple sclerosis: increased expression of interleukin-2 receptors on lymphocytes. 1986;36(10):1392-5. [DOI:10.1212/WNL.36.10.1392] [PMID]
18. Merrill JE, Mohlstrom C, Uittenbogaart C, Kermaniarab V, Ellison GW, Myers LW. Response to and production of interleukin 2 by peripheral blood and cerebrospinal fluid lymphocytes of patients with multiple sclerosis. J Immunol. 1984;133(4):1931-7.
19. Selmaj K, Nowak Z, Tchórzewski H. Interleukin-1 and interleukin-2 production by peripheral blood mononuclear cells in multiple sclerosis patients. J Neurol Sci. 1988;85(1):67-76. [DOI:10.1016/0022-510X(88)90036-6]
20. Brajczewska-Flsher W, Iwmska B; Kruszewska J, Kodak J, Czlonkowska A. Interleukin 1 and 2 production by peripheral blood mononuclear cells in subacute sclerosing panencephalitis and exacerbation of multiple sclerosis. Acta Neurol Scand. 1989;80(5):390-393. [DOI:10.1111/j.1600-0404.1989.tb03899.x] [PMID]
21. Trotter JL, Clifford DB, McInnis JE, R C Griffeth, K A Bruns, M S Perlmutter, et al. Correlation of immunological studies and disease progression in chronic progressive multiple sclerosis. An Neurol. 1989;25(2):172-8. [DOI:10.1002/ana.410250211] [PMID]
22. Sayad A, Allameh A, Sayad A, Noruzinia M, Akbari MT, Sarzaeem A, et al. The association of -475 and -631 interleukin-2 gene polymorphism with multiple sclerosis. International Journal of Immunogenetics. Cell journal. 2013;41(4):330-334. [DOI:10.1111/iji.12132] [PMID]
23. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121-7. [DOI:10.1002/ana.1032] [PMID]
24. Van Heel DA, Franke L, Hunt KA, Gwilliam R, Zhernakova A, Inouye M, et al. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL-2 and IL-21. Nat Genet. 2007;39(7):827-9. [DOI:10.1038/ng2058] [PMID] [PMCID]
25. Sayad A, Sayad A, Allameh A, Mohseni Y. Correlation of interleukin-2 and uric acid plasma concentration with multiple sclerosis in Iranian patients. Journal of Biology and Today's World. 2013;2(4):72-75. [DOI:10.15412/J.JBTW.01020402]
26. Aĭtxozhina NA, Nigmatova VG, Khanseitova AK, Mendesh MA, Ashirbekov EE, Balmukhanov TS. Polymorphic markers of some genes associated with multiple sclerosis in the population of Kazakhstan. Genetika. 2011;47(6):847-52 [DOI:10.1134/S1022795411060020]
27. Ward SB, Hernandez-Hoyos G, Chen F, Waterman M, Reeves R, Rothenberg EV. Chromatin remodeling of the interleukin-2 gene: distinct alterations in the proximal versus distal enhancer regions. Nucleic Acids Res. 1998;26(12):2923-2934. [DOI:10.1093/nar/26.12.2923] [PMID] [PMCID]
28. Asouri M, Rokni H A, Sahraian M A, Fattahi S, Motamed N, Doosti R, et al. Association of HLA-DRAand IL-2RA Polymorphisms with the Severity and Relapses Rate of Multiple Sclerosis in an Iranian Population. Rep Biochem Mol Biol. 2020;9(2):129-137. [DOI:10.29252/rbmb.9.2.129] [PMID] [PMCID]
29. Moghadam ASF, Ataei M, Arabzadeh G, Falahati K, Roshani F, Sanati MH. Analysis of MicroRNA-18a Expression in Multiple Sclerosis Patients. Rep Biochem Mol Biol. 2020:8(4):429-437.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
